Colorectal Cancer

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

The combination of tilsotolimod plus ipilimumab failed to improve objective response rate over ipilimumab alone in patients with advanced melanoma who are refractory to a PD-1 inhibitor, missing the primary end point of the phase 2 ILLUMINATE-301 trial.

Cathy Eng, MD, FACP, FASCO, discusses results from the extended RAS analysis of the phase 3 EPIC trial in patients with metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Syed Kazmi, MD, discusses emerging biomarkers that could help guide treatment decisions in patients with colorectal cancer.

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

Determining the appropriate sequencing for chemotherapy and radiation in patients with locally advanced rectal cancer is important and may depend on whether the goal of therapy is nonoperative management.

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Cathy Eng, MD, FACP, FASCO, and Jordan D. Berlin, MD discuss pressing questions in hepatocellular carcinoma, colorectal cancer, gastric cancer, neuroendocrine tumors, and pancreatic cancer.

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Atrayee Basu-Mallick, MD, discusses the role of circulating tumor DNA in patients with colorectal cancer.